CD16A Binding Agents and Uses Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,572,370 | CD16A Binding Agents and Uses Thereof In force · High confidence UsedRemaining | Biohaven Therapeutics Ltd. | In force | High confidence | ||
| US 12,162,892 | CD16A Binding Agents and Uses Thereof In force · High confidence | Kleo Pharmaceuticals, Inc. | In force | High confidence | ||
| Application 18/909,629 | CD16A Binding Agents and Uses Thereof Pending Not granted | Kleo Pharmaceuticals, Inc. | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Kleo Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.